Clinical review report: Tocilizumab (Actemra) (Hoffmann-La Roche Limited)
The objective of this report was to perform a systematic review of the beneficial and harmful effects of tocilizumab 162 mg/0.9 mL pre-filled syringe for subcutaneous (SC) injection for the treatment of giant cell arteritis (GCA) in adults
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2018, April 2018
|
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this report was to perform a systematic review of the beneficial and harmful effects of tocilizumab 162 mg/0.9 mL pre-filled syringe for subcutaneous (SC) injection for the treatment of giant cell arteritis (GCA) in adults |
|---|---|
| Item Description: | "Version: final." |
| Physical Description: | 1 PDF file (63 pages) illustrations |